Diabetes Australia has welcomed the TGA approval of Foundayo (orforglipron), a brand new oral GLP-1 receptor agonist for the administration of sort 2 diabetes and power weight administration in eligible adults.
Foundayo was entered on the Australian Register of Therapeutic Items on 16 November 2026.
The brand new drugs supplies a once-daily oral therapy choice, providing an alternate for eligible individuals who might want a pill to a self-administered injection. It may be taken with out particular meals or water restrictions, offering extra flexibility for individuals who use it.
Diabetes Australia Group CEO Justine Cain welcomed the approval, saying extra therapy choices had been constructive for individuals residing with sort 2 diabetes and other people requiring medical therapy for weight problems, whereas noting that regulatory approval didn’t essentially assure inexpensive or equitable entry.
“GLP-1 medicines have considerably expanded therapy choices for many individuals residing with sort 2 diabetes and weight problems, and it’s encouraging to see new formulations changing into accessible,” Ms Cain stated.
“Importantly, regulatory approval doesn’t robotically imply {that a} drugs will likely be inexpensive or equitably accessible to everybody who may gain advantage.
“As new remedies emerge, we have to be sure that choices about entry and affordability are guided by robust medical proof and well being want, slightly than an individual’s capability to pay.
“For some individuals, the price of these medicines stays a major barrier. We have to proceed evidence-based approaches to subsidised entry in order that people who find themselves clinically probably to profit should not excluded as a result of they can’t afford therapy.
“Innovation is necessary, however so is equitable entry. A therapy can solely enhance well being outcomes if the individuals who stand to profit can really entry it.”
Ms Cain stated the introduction of recent GLP-1 medicines additionally highlighted the significance of guaranteeing medicines had been offered as a part of complete, person-centred healthcare.
“As entry to GLP-1 medicines expands, we additionally want to make sure individuals obtain acceptable medical care and assist, together with vitamin, bodily exercise, psychological assist the place wanted, and long-term follow-up,” Ms Cain stated.
“It’s equally necessary to make sure these remedies are prescribed appropriately, used safely and ship the best attainable well being profit.”
TGA approval and registration on the Australian Register of Therapeutic Items is distinct from PBS subsidy.
Foundayo’s registration by the TGA doesn’t imply that the drugs will likely be subsidised by way of the Pharmaceutical Advantages Scheme.
Diabetes Australia encourages individuals desirous about GLP-1 medicines to talk with their GP, endocrinologist, pharmacist or different appropriately certified healthcare skilled in regards to the potential advantages, dangers and suitability of therapy for his or her particular person circumstances.